An approach to experimental scleroderma, using urinary glycosaminoglycans from patients with systemic scleroderma

Area of Science:

• Connective tissue research
• Pathology
• Biochemistry

Background:

• Systemic scleroderma is a complex fibrotic disease affecting skin and internal organs.
• Glycosaminoglycans (GAGs) play crucial roles in extracellular matrix structure and function.
• Urinary GAGs may contain disease-specific biochemical markers.

Purpose of the Study:

• To investigate the potential fibrogenic effects of urinary GAGs from systemic scleroderma patients.
• To determine if these GAGs can induce scleroderma-like changes in a mouse model.
• To analyze the ultrastructural impact of these GAGs on connective tissues.

Main Methods:

• Intraperitoneal injection of crude GAGs isolated from the urine of systemic scleroderma patients into mice.
• Histopathological and ultrastructural examination of mouse skin and esophagus.
• Analysis of GAG composition, focusing on heparan sulfate variants.

Main Results:

• Frequent observation of fibrotic processes in the skin and esophagus of injected mice.
• Scleroderma-like changes were particularly pronounced when GAGs contained probable heparan sulfate variants.
• Ultrastructural alterations in collagen fibers and GAGs of the skin were noted.

Conclusions:

• Urinary GAGs from systemic scleroderma patients, especially heparan sulfate variants, can induce fibrotic changes resembling human scleroderma in mice.
• These findings suggest a potential role for specific GAGs in the pathogenesis of systemic scleroderma.
• The study provides insights into the extracellular matrix alterations occurring in scleroderma.